Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 1, 2016
Event: Entry into a Material Definitive Agreement with UCB Biopharma Sprl.
Key Financial Metrics
This filing reports a specific transaction rather than periodic financial performance. Consequently, standard metrics such as revenue, profit, cash flow, margins, and debt are not provided in this document.
- Upfront Payment: $5.0 million payable to UCB.
- Development/Regulatory Milestones: Up to $119.5 million contingent on achievement of certain events.
- Sales Milestones: Up to $250 million contingent on annual sales thresholds.
- Royalties: Low double-digit percentage on sales, subject to reduction.
Material Changes
On July 1, 2016, Syndax entered into an exclusive, worldwide, sublicenseable license agreement for UCB6352 (renamed SNDX-6352), an IND-ready anti-CSF-1R monoclonal antibody. This represents a significant expansion of the Company's pipeline and potential future cash outflows.
Outlook, Risks, and Management Commentary
Development Responsibility: Syndax is solely responsible for the development and commercialization of SNDX-6352, with UCB performing only limited transitional manufacturing tasks.
Termination Rights:
- Either party may terminate for uncured material breach or insolvency.
- Syndax may terminate at will with advance written notice.
- UCB may terminate if Syndax challenges the validity of licensed patent rights.
Risks and Uncertainties: The filing includes a cautionary note regarding forward-looking statements. Actual results may differ due to factors including unexpected safety/efficacy data, clinical trial enrollment rates, regulatory changes, and litigation risks.
Investor Verification Checklist
- Verify the impact of the $5.0 million upfront payment on current cash reserves and liquidity.
- Review the specific definitions of the development and regulatory milestones triggering the $119.5 million in potential payments.
- Confirm the timeline for the IND (Investigational New Drug) application for SNDX-6352.
- Assess the competitive landscape for anti-CSF-1R monoclonal antibodies.
- Monitor the Company's ability to fund future development obligations without additional capital raises.